10x Genomics, Inc. (TXG) Income Statement
TXG 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTXG revenue and net income
Where TXG's revenue goes
2025Each bar shows an amount and its share of revenue. TXG kept −6.8% of revenue as net income.
TXG profit margins
TXG growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +5.2% | +7.6% | +16.6% | — |
| Gross profit | +7.1% | +3.9% | +13.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TXG quarterly EPS vs estimates
10x Genomics beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.27).
TXG income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M | $298.8M | $245.9M | $146.3M | $71.1M |
| Cost of revenue | $198.9M | $196.3M | $209.4M | $120.4M | $74.1M | $58.5M | $61.0M | $28.7M | $10.6M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M | $240.4M | $184.9M | $117.7M | $60.5M |
| Research & development | $238.6M | $264.7M | $270.3M | $265.7M | $211.8M | $123.4M | $83.1M | $47.5M | $32.2M |
| Sales, general & admin | $316.1M | $344.3M | $343.3M | $298.3M | $257.6M | $202.3M | $130.8M | $87.9M | $46.7M |
| Total operating expenses | $554.8M | $609.0M | $674.6M | $564.0M | $469.3M | $325.7M | $213.9M | $135.5M | $78.9M |
| Operating income | −$110.9M | −$194.6M | −$265.3M | −$167.9M | −$52.9M | −$85.3M | −$29.1M | −$110.8M | −$18.4M |
| Interest income | $20.0M | $18.4M | $16.9M | $6.6M | $206,000 | $1.5M | $2.8M | $1.0M | $308,000 |
| Interest expense | $0 | $4,000 | $33,000 | $476,000 | $866,000 | $1.7M | $3.1M | $2.4M | $811,000 |
| Income before taxes | −$39.9M | −$177.7M | −$248.8M | −$162.0M | −$53.7M | −$534.5M | −$31.0M | −$112.4M | −$18.7M |
| Income taxes | $3.6M | $4.9M | $6.3M | $4.0M | $4.5M | $8.3M | $218,000 | $87,000 | $21,000 |
| Net income | −$43.5M | −$182.6M | −$255.1M | −$166.0M | −$58.2M | −$542.7M | −$31.3M | −$112.5M | −$18.8M |
| EBITDA | $3.9M | −$134.0M | −$205.1M | −$128.5M | −$24.6M | −$513.8M | −$20.9M | −$106.1M | −$13.6M |
| EPS (diluted) | $0.23 | −$0.35 | −$0.72 | −$0.25 | −$0.53 | −$0.94 | −$0.56 | −$8.03 | −$1.56 |
| Gross margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating margin | −17.2% | −31.9% | −42.9% | −32.5% | −10.8% | −28.6% | −11.8% | −75.7% | −25.8% |
| Net margin | −6.8% | −29.9% | −41.2% | −32.1% | −11.9% | −181.6% | −12.7% | −76.9% | −26.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $151.0M | $150.8M | $166.0M | $149.0M | $172.9M | $154.9M | $165.0M | $151.7M | $153.1M | $141.0M | $184.0M | $153.6M |
| Cost of revenue | $38.5M | $44.7M | $53.0M | $48.7M | $47.8M | $49.4M | $54.1M | $45.3M | $48.9M | $48.1M | $68.2M | $58.1M |
| Gross profit | $112.5M | $106.2M | $113.0M | $100.3M | $125.1M | $105.4M | $111.0M | $106.4M | $104.2M | $92.9M | $115.8M | $95.5M |
| Research & development | $56.8M | $56.8M | $56.0M | $57.2M | $61.2M | $64.2M | $67.0M | $66.2M | $62.9M | $68.6M | $65.3M | $107.9M |
| Sales, general & admin | $78.7M | $66.4M | $76.6M | $75.4M | $74.4M | $89.7M | $93.8M | $81.7M | $83.0M | $85.8M | $86.1M | $82.4M |
| Total operating expenses | $132.1M | $123.2M | $132.6M | $132.5M | $95.0M | $144.8M | $160.8M | $147.9M | $146.0M | $154.4M | $171.0M | $190.3M |
| Operating income | −$19.6M | −$17.0M | −$19.5M | −$32.2M | $30.1M | −$39.3M | −$49.8M | −$41.5M | −$41.7M | −$61.5M | −$55.2M | −$94.8M |
| Interest income | $4.8M | $5.0M | $6.9M | $5.2M | $4.3M | $3.7M | $4.0M | $5.0M | $4.7M | $4.7M | $4.6M | $4.3M |
| Interest expense | $0 | — | — | $3,000 | $3,000 | $0 | $8,000 | $2,000 | $1,000 | $1,000 | $8,000 | $1,000 |
| Income before taxes | −$18.6M | −$12.8M | −$15.2M | −$28.2M | $37.0M | −$33.5M | −$48.4M | −$34.4M | −$37.1M | −$57.8M | −$46.6M | −$91.7M |
| Income taxes | −$714,000 | $623,000 | $1.1M | −$733,000 | $2.5M | $852,000 | $648,000 | $1.3M | $818,000 | $2.1M | $2.4M | $1.2M |
| Net income | −$17.9M | −$13.5M | −$16.3M | −$27.5M | $34.5M | −$34.4M | −$49.0M | −$35.8M | −$37.9M | −$59.9M | −$49.0M | −$93.0M |
| EBITDA | −$9.0M | −$937,000 | $63.5M | −$16.0M | $46.7M | −$23.7M | −$37.8M | −$23.7M | −$26.2M | −$46.3M | −$34.9M | −$80.3M |
| EPS (diluted) | −$0.14 | $0.07 | $0.07 | −$0.02 | $0.28 | −$0.10 | −$0.14 | −$0.02 | $0.01 | −$0.20 | −$0.41 | −$0.10 |
| Gross margin | 74.5% | 70.4% | 68.1% | 67.3% | 72.3% | 68.1% | 67.2% | 70.2% | 68.1% | 65.9% | 62.9% | 62.2% |
| Operating margin | −12.9% | −11.3% | −11.8% | −21.6% | 17.4% | −25.4% | −30.2% | −27.4% | −27.3% | −43.6% | −30.0% | −61.7% |
| Net margin | −11.9% | −8.9% | −9.8% | −18.4% | 20.0% | −22.2% | −29.7% | −23.6% | −24.8% | −42.5% | −26.6% | −60.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TXG's financial statements (latest annual report filed February 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TXG financial results
In fiscal year 2025 (ended December 31, 2025), 10x Genomics reported revenue of $642.8 million, up 5.2% from the year before. It had a net loss of $43.5 million, a net profit margin of −6.8%. Diluted earnings per share came to $0.23. Over five years revenue grew at an average rate of 16.6% a year.
See the TXG stock overview for the latest quote and news, or the TXG chart for price history and technical indicators.
TXG income statement FAQ
What is 10x Genomics's annual revenue?
10x Genomics reported total revenue of $642.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 5.2% from $610.8 million the previous year.
Is 10x Genomics profitable?
No. 10x Genomics reported a net loss of $43.5 million in fiscal 2025, a net profit margin of −6.8%; its operating margin was −17.2%.
What is 10x Genomics's gross margin?
10x Genomics's gross margin was 69.1% in fiscal 2025: for every $100 of revenue, 10x Genomics kept $69 after the direct cost of its products and services.
How much does 10x Genomics spend on research and development?
10x Genomics spent $238.6 million on research and development in fiscal 2025, 37.1% of revenue.
How fast is 10x Genomics growing?
Revenue grew 16.6% a year on average over the last five fiscal years, from $298.8 million to $642.8 million.
What are 10x Genomics's earnings per share?
10x Genomics earned $0.23 per diluted share in fiscal 2025, compared with $-0.35 a year earlier.
When will 10x Genomics report its next earnings?
10x Genomics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does 10x Genomics's fiscal year end?
10x Genomics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 13, 2026.